A phase 3 registrational trial evaluating the efficacy and safety of switching to tobevibart and elebsiran in Chronic Hepatitis delta (CHD) patients who have not achieved viral suppression with bulevirtide
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Elebsiran (Primary) ; Tobevibart (Primary) ; Bulevirtide
- Indications Hepatitis D
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ECLIPSE 2
- 26 Mar 2025 New trial record
- 13 Mar 2025 According to a Vir Biotechnology media release, this study is a part of the company's registrational program named ECLIPSE, comprised of two Phase 3 studies (ECLIPSE 1 and ECLIPSE 2) and one phase 2b study (ECLIPSE 3). ECLIPSE program is designed to enable regulatory submissions to multiple regulatory agencies and to support reimbursement and access. ECLIPSE 1 and 2 will provide the registrational efficacy and safety data; ECLIPSE 3 will provide important supportive data.